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Background: Calcium channel blockers such as conotoxins have shown a great potential to reduce brain and
spinal cord injury. MVIIC neuroprotective effects analyzed in in vitro models of brain and spinal cord ischemia
suggest a potential role of this toxin in preventing injury after spinal cord trauma. However, previous clinical studies
with MVIIC demonstrated that clinical side effects might limit the usefulness of this drug and there is no research
on its systemic effects. Therefore, the present study aimed to investigate the potential toxic effects of MVIIC on
organs and to evaluate clinical and blood profiles of rats submitted to spinal cord injury and treated with this
marine toxin. Rats were treated with placebo or MVIIC (at doses of 15, 30, 60 or 120 pmol) intralesionally following
spinal cord injury. Seven days after the toxin administration, kidney, brain, lung, heart, liver, adrenal, muscles,
pancreas, spleen, stomach, and intestine were histopathologically investigated. In addition, blood samples collected
from the rats were tested for any hematologic or biochemical changes.
Results: The clinical, hematologic and biochemical evaluation revealed no significant abnormalities in all groups,
even in high doses. There was no significant alteration in organs, except for degenerative changes in kidneys at a
dose of 120 pmol.
Conclusions: These findings suggest that MVIIC at 15, 30 and 60 pmol are safe for intralesional administration after
spinal cord injury and could be further investigated in relation to its neuroprotective effects. However, 120 pmol
doses of MVIIC may provoke adverse effects on kidney tissue.
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Spinal cord injury (SCI) is a leading cause of permanent
disability in young adults [1-3]. At the time of trauma,
the primary lesion usually leads to the disruption of axons,
neurons and neuroglia cell bodies, resulting in nerve im-
pulses interruption. Afterwards, the secondary neurode-
generative events start and worsen the initial injury.
Excessive accumulation of intracellular calcium is a com-
mon phenomenon after SCI and it is the most critical step
in ionic dysregulation that generates axonal injury and* Correspondence: kamoliveira@yahoo.com.br
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unless otherwise stated.eventual apoptosis or necrosis via an increase in cellular
enzymes activation, mitochondrial damage, acidosis, and
free radicals production [4-9].
Calcium channel blockers (CCB) have shown great po-
tential in reducing brain and spinal cord injury, by pre-
venting the intense ion influx and, consequently, the
secondary injury progression [10,11]. A wide variety of
natural CCB were identified in animal venoms contain-
ing neuroactive or neuroprotective peptides, including
the conotoxins from Conus snails [12]. Omega-conotoxin
MVIIC (MVIIC) is a member of the CCB toxin family
constituted by 26 aminoacids [13]. It selectively inhibits
the types N (Cav2.1), P, and Q (Cav2.2) voltage-dependent
calcium channels (VDCC) that are essential in the releaseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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MVIIC effects have shown that it significantly reduces cal-
cium influx through VDCC in several in vitro models of
ischemic brain and spinal injuries [15,17-21]. Thus, these
findings suggest a potential role of MVIIC in preventing
secondary injuries after spinal trauma.
However, early clinical experience with MVIIC dem-
onstrates that side effects may limit the usefulness of this
class of drugs [22,23]. Envenomation by Conus toxins is
characterized by various symptoms such as intense pain
followed by shaking, generalized paresthesia, neuromus-
cular paralysis and death caused by respiratory failure
[23,24]. No information about the pharmacokinetics and
pharmacodynamic characteristics of MVIIC is available.
To be possible to evaluate the effects of toxin on SCI,
safety should be the overriding principle in the selection
for the best dose. The present study was designed to de-
termine, for the first time, the in vivo effects of MVIIC on
blood profile and histopathological changes that it may
provoke. In this experiment, MVIIC was intralesionally
injected due to its peptide nature, so the toxin was directly
administered in the central nervous system (CNS), and
additionally this route enables local treatment, requiring a
smaller amount of toxin with fewer side effects [25,26].
Methods
Experimental design
Thirty adult male Wistar rats weighting 400 to 450 g were
randomly distributed into five groups. Rats were housed in
a controlled environment and provided with commercial
rodent food and water ad libitum. The Ethics Committee
on Animal Experimentation of the Federal University of
Minas Gerais (CETEA/UFMG) approved the present
study under protocol n. 075/10. All animals experiments
followed the recommendations of Guide for the Care
and Use of Laboratory Animals of the US National Insti-
tute of Health.
Animals were premedicated with tramadol chloride
(4 mg/kg, subcutaneously), and anesthesia was induced
and maintained with isoflurane in a non-rebreathing cir-
cuit, through a facemask. The animals were positioned
in a stereotaxic apparatus, received prophylactic anti-
biotic with cephalotin (60 mg/kg, subcutaneously) and
then, prepared for asseptic surgery. An incision was
made in the dorsal midline skin and subcutaneous tis-
sues from T8 to L1, and the muscle and tissue overlying
the spinal column were blunt-dissected away revealing
the laminae. Using the spiny process of T13 as a landmark,
laminectomy of T12 was performed with a pneumatic drill
and the lamina was carefully removed to expose the spinal
cord. Extradural compression of the spinal cord at the
vertebral level of T12 was achieved as previously de-
scribed [27-30] using a weight of 70 g/cm2. Five minutes
later, an intralesional injection was performed accordingto the experimental protocol. The incision was closed in
two layers and the animals were allowed to recover from
anesthesia in a warmed (37°C) box.
Post-operative care procedures involved manual expres-
sion of the bladder, three times a day, tramadol chloride
(2 mg/kg, orally, every eight hours) for three days, and
cephalexin (30 mg/kg, orally, twice a day) for five days.
Pharmacological treatment
Five minutes after the incision, 2 μL of treatment was
administered into the injury center using a Hamilton
microsyringe, as previously described [31]. The animals
were distributed into five groups, with six rats each, ac-
cording to the treatment protocol: placebo treatment with
sterile water (PLA), 15 pmol of MVIIC (G15), 30 pmol of
MVIIC (G30), 60 pmol of MVIIC (G60), and 120 pmol of
MVIIC (G120). Doses were based on studies describing
that MVIIC doses of 3 pmol have analgesic effects by
blocking the VDCC type P/Q, and those of 100 pmol had
side effects [23,32].
For eight days, experiments focused on clinical obser-
vation. All animals were euthanized at Day 8 following
SCI. Clinical and histopathological evaluations were car-
ried out by investigators who did not take part into the
research.
Clinical evaluation
For three days before SCI, animals were allowed to adapt
to the open field arena – that had 90 cm in diameter
and three inches high – for 15 minutes to clinical evalu-
ation. After trauma, they were monitored for the pres-
ence of widespread tremor, walking in circle or muscle
weakness, during the first five hours after the toxin ad-
ministration and daily until euthanasia [33].
Blood collection
Blood samples were collected prior to experiment and
eight days after treatment by caudal vein puncture in
two types of tubes, with anticoagulant sodium fluoride
in order to access hematologic profile, and without anti-
coagulant to collect serum and evaluate biochemical
profiles, both analyzed immediately.
Hematological parameters
Hematological parameters including red blood cells (RBC),
white blood cells (WBC) and hemoglobin concentration
(Hb) were determined using Abacus Junior Vet electronic
counter (Diatron Messtechnik GmbH, Austria). The RBC
indices – namely mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH) and mean corpuscular
hemoglobin concentration (MCHC) – were calculated
using the RBC count, Hb and hematocrit (Ht) values.
Blood smears were prepared on glass slides (26 ×
79 mm), fixed with May-Grunwald solution and stained
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of leukocytes and total number of platelets [34]. Volume
of packed RBC or Ht was determined using a micro-
hematocrit centrifuge (Model Spin 1000®, Micro Spin,
USA). The blood was centrifuged to obtain plasma and
to determinate total protein by refractometry.
Biochemical parameters
Urea, creatinine, alanine aminotransferase (ALT) and as-
partate aminotransferase (AST) were determined with
the aid of commercial kits from Synermed® (Westfield,
USA) and Cobas Mira Classic® chemical analyzer (Global
Medical Instrumentations, USA).
Histological analysis of tissue injury
On Day 8 after surgery, the rats were deeply anesthetized
with an overdose of sodium thiopental (100 mg/kg), intra-
peritoneally. The animals were perfused with 300 mL of
0.9% sodium chloride saline followed by 300 mL of 10%
phosphate-buffered formalin (pH 7.4). Following perfu-
sion, the brain, heart, liver, kidney, lung, spleen, stomach,
lumbar muscle, intestine, pancreas and adrenal were re-
moved and placed overnight in 10% phosphate-buffered
formalin. Twenty-four hours later, organ samples were
dehydrated in a series of alcohol grades and embedded in
paraffin wax. Briefly, 4-μm thick longitudinal sections
were stained with routine hematoxylin-eosin (HE) for
pathological studies.
Lesion areas were classified in nine grades, according
to the histological pattern of intensity (mild, moderate,
and severe) and extension (focal, multifocal, and diffuse)
of the lesion (Table 1).
Statistical analysis
All collected data were analyzed using Prism 5® for
Windows (GraphPad Software, La Jolla, USA) and were
expressed as mean ± standard deviation (SD). Normal












9 Severe Diffuse(ANOVA), followed by t-paired test between times and
Student-Newman-Keuls test between groups. Non-
parametric parameters were subjected to Kruskall-
Wallis test and Dunn’s post hoc test (p < 0.05).
Results and discussion
In the current experiment, we studied the clinical,
hematological, biochemical and tissue histopathological
changes to investigate any toxic effects caused by MVIIC.
These parameters help to identify possible changes caused
by such toxins, the severity of the alterations and which
doses can be clinically used in SCI.
Clinical evaluation
Although frequently reported, in the present study no
dose provoked muscle weakness or paralysis as seen by
Dalmolin et al. [23] at 100 or 300 pmol by intrathecal
(IT) route or even shaking at 10 pmol by intracerebroven-
tricular (IC) route. These differences may be attributable
to the fact that it was impossible to evaluate variables such
as hindlimb locomotor deficit, flaccid paralysis or de-
creased tail withdrawal response, describe by these au-
thors, because they are similar to clinical signs of SCI.
Besides, Malmberg and Yaksh [33] noticed that body shak-
ing occurred 30 minutes after the injection and, at this
time, the animal was recovering from anesthesia. More-
over, Dalmolin et al. [23] observed that IC route had more
side effects than IT. This fact could be associated to the
high density of P/Q-type expressed in nociceptive path-
ways at the supraspinal site, which emphasizes the power-
ful effect of MVIIC injected by IC route [35]. It also could
be inferred that due to the IL injection into the spinal
cord, we did not notice even body shaking as seen at 10
pmol by IC route.
Hematological parameters
In this experiment, an increase in RBC, Ht (Figure 1)
and Hb (Figure 2) concentration in all groups may be
due to the postoperative stress, restraint and anesthesia
prior to euthanasia, leading to a splenic contraction and
consequent erythrocyte release [36]. Furthermore, hemo-
concentration is most likely a result of the liquid loss
due to the weakened condition of rats in the postopera-
tive period and reduced water consumption. Dehydra-
tion was not clinically observed, but water intake was
reduced as suggested the levels of bottles. Moreover, in
the dehydration process, total protein concentration is
augmented [37]. Proteins have many functions in the or-
ganism and their levels helps in the diagnosis and progno-
sis of hydration status, inflammation, infection, nutritional
status and changes in protein synthesis [38]. In this
study, the absolute values of total protein showed no
differences among times and groups (Additional file 1),
suggesting that hematological changes are likely related
Figure 1 Effects of different doses of MVIIC on red blood cells (× 106/μL) and hematocrit. Mean number ± SD of red blood cells and
hematocrit of rats submitted to compressive spinal cord injury and treated with placebo (PLA, positive control) or ω-conotoxin MVIIC (G15, 15
pmol MVIIC; G30, 30 pmol MVIIC; G60, 60 pmol MVIIC), preoperatively (white column) and eight days after treatment (gray column) (*p < 0.05;
**p < 0.01). Red blood cells and hematocrit normal values are, respectively, 7.62 - 9.99 × 106/μL and 38.5-52%, as described by Giknis and
Clifford [39].
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parameters remained close to the reference values for the
species [39].
The values of MCV (Additional file 2), MCH (Additional
file 3) and MCHC (Additional file 4) did not differ among
times or groups, remaining within the physiologic pat-
terns of species.
The increase of platelets (Figure 2) is a common finding
in patients who underwent surgical intervention probably
by tissue damage and inflammation. The relevance of this
event is not clear yet [40-42]. Despite this fact, the param-
eters were within physiological standards for these animals
(574–1253 × 103 cells/μL) [39].
There are no reports of hematologic evaluation in ani-
mals that receive MVIIC, and this study shows that it
does not cause anemia, hemolysis, vascular changes or
interference in the hematologic response when applied
by intralesional route.
There was a significant increase of the total leukocyte
count in the PLA (7.680 ± 2.140 cells/μL) among the
times of collection, not exceeding the maximum limits
for the species (Figure 3) (p < 0.05). The leukocytosis canFigure 2 Effects of different doses of MVIIC on hemoglobin (g/dL) an
platelets of rats submitted to compressive spinal cord injury and treated w
MVIIC; G30, 30 pmol MVIIC; G60, 60 pmol MVIIC), preoperatively (white colu
Hemoglobin and platelets concentration normal values are, respectively, 13
Clifford [39].be attributed to stress induced by physical restraint at
the time of euthanasia. In acute stress conditions, the re-
lease of endogenous glucocorticoids promotes increased
blood and lymph circulation so leukocytes pass into the
peripheral blood causing physiological leukocytosis [43].
However, only the PLA group showed this significant
leukocyte increase. Another possible explanation is that
in animals with spinal cord trauma, there is great local
inflammatory reaction in PLA group. In contrast, MVIIC
groups did not show significant leukocyte augmentation
and we can infer a possible anti-inflammatory effect, re-
quiring further investigation.
There was no change in the absolute number of mono-
cytes (Additional file 5), neutrophils (Additional file 6), and
basophils (Additional file 7) among groups or times. Re-
garding the number of lymphocytes, it can be observed a
significant increase (p < 0.05) in animals of PLA group
(5.750 ± 1.250) eight days after the injury (Figure 3). Lym-
phocytes are the major circulating cells of rats, so the
leucocytosis is probably due to lymphocytosis. Moreover,
there was no difference among times and groups related to
the absolute number of eosinophils, showing that MVIICd platelets (× 103/μL). Mean number ± SD of hemoglobin and
ith placebo (PLA, positive control) or ω-conotoxin MVIIC (G15, 15 pmol
mn) and eight days after treatment (gray column) (*p < 0.05).
.5-17.4 g/dL and 574–1253 × 103/μL, as described by Giknis and
Figure 3 Effects of different doses of MVIIC on total leukocytes (cells/μL) and lymphocytes (cells/μL). Mean number ± SD of total
leukocytes and lymphocytes of rats submitted to compressive spinal cord injury and treated with placebo (PLA, positive control) or ω-conotoxin
MVIIC (G15, 15 pmol MVIIC; G30, 30 pmol MVIIC; G60, 60 pmol MVIIC), preoperatively (white column) and eight days after treatment (gray column)
(*p < 0.05). Total leukocyte and lymphocyte normal values are, respectively, 1980–11060 cells/μL and 1190–9450 cells/μL, as described by Giknis
and Clifford [39].
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philia [44].
As seen before, there was no toxic effect of treatment
and, therefore, the toxin at the tested doses did not
cause any hematological change. These results are un-
precedented in the literature.
Biochemical parameters
Biochemical analysis is an important variable for evalu-
ation in studies on toxins which reflects hepatic and
renal function. Some enzymes such as AST and ALT are
used to evaluate liver function, a key organ for drug
metabolism. They reveal abnormalities, and deleteriousFigure 4 Effects of different doses of MVIIC on biochemical paramete
aspartate aminotransferase (AST) (U/L), urea (mg/dL) and creatinine (mg/dL) i
Controls were injected with sterile water (PLA) and other groups received diff
creatinine normal values are, respectively, 19–48 U/L, 63–175 U/L, 10.7-20 mgeffects of toxins may increase their levels, especially
ALT, which is more specific for liver changes in rats
[45]. In our findings, there was no difference in the
values of AST and ALT among time points (Figure 4), so
there was no toxic effect on liver tissue, which was con-
firmed by liver histopathology. In addition to reflecting
liver abnormalities, AST is used to assess myocardial in-
farction. Thus, according to our results, it can be stated
that there was no significant cardiac muscle damage
confirmed by heart histopathology.
Furthermore, renal excretion is a major route for drug
elimination and their commitment may be evidenced by
increases in serum creatinine and urea, indicators ofrs. Mean number ± SD of alanine aminotransferase (ALT) (U/L),
n different times (preoperatively and eight days after injection) (p < 0.05).
erent doses of MVIIC (15, 30, 60 and 120 pmol). ALT, AST, urea and
/dL and 0.3-0.5 mg/dL, as described by Giknis and Clifford [39].
Figure 5 Median scores for renal amyloidosis in rats submitted
to spinal cord injury. Controls were injected with sterile water
(PLA) and other groups received different doses of MVIIC (15, 30, 60
and 120 pmol). Lowercase letters express statistically differences
among groups, after eight days of spinal cord injury (Kruskal-Wallis
test and Dunn’s post hoc test; p < 0.05).
Oliveira et al. Journal of Venomous Animals and Toxins including Tropical Diseases 2014, 20:15 Page 6 of 8
http://www.jvat.org/content/20/1/15glomerular filtration. Creatinine is considered a more re-
liable indicator that may be affected by the influence of
extrarenal factors, and it is the final product of energy
used by muscle tissue [46]. Its concentration in blood
depends on muscle injury, physical efforts and also meat
intake in the case of carnivorous. It is filtered by the
renal glomeruli, so renal glomerular lesions are verified
by increased creatinine and urea [46,47]. These values
did not differ among groups and times (Figure 4). How-
ever, high levels of urea and creatinine in comparison
with the physiological data set by Giknis and Clifford
[39] were noticed, both preoperatively and on the eighthFigure 6 Light microscopy of renal longitudinal sections of rats staine
changes in tubules (arrow) and glomeruli (asterisk) in the control group (PL
of MVIIC (G120), revealing severe degeneration in the Bowman’s space, glo
eosinophilic material inside renal tubules (arrow) (207×).day after trauma. Therefore, different standard physio-
logical data from the literature were observed.
Histopathological evaluation
Histopathological studies revealed no significant abnormal-
ities in tissue of brain, lung, heart, liver, adrenal, muscle,
pancreas, spleen, and stomach in all groups.
In our study kidney tissues showed degenerative
changes, especially when treated with 120-pmol doses
of MVIIC, including degeneration in the Bowman’s
space, glomerular and tubular epithelial cells with de-
position of eosinophilic material (amyloid) inside renal
tubules, atrophy and glomerular sclerosis [48]. The 120-
pmol dose significantly differed from others groups
(p < 0.05) (Figures 5 and 6). This type of injury may lead
to renal failure and have been observed in animals after
spinal trauma following spider or scorpion envenom-
ation [49-51]. It seems that in addition to amyloidosis
caused by SCI, the 120-pmol dose intensified the kidney
injury, even without increased levels of urea and cre-
atinine, since it occurs when over 75% of renal function
is lost [47]. Although there is no record of systemic effects
of MVIIC, the highest dose increased renal changes,
possibly by a direct glomerulopathy to renal tubule, or
indirect, inflammatory response, as seen with others
drugs [52].
Conclusion
Our results suggest that MVIIC at 15, 30 and 60 pmol
are safe to be used via intralesional route after spinal
cord injury. The 120-pmol dose of MVIIC was detrimen-
tal to renal tissue, but it was not enough to change the
renal function. More studies are necessary to investigated with hematoxylin-eosin. (A) Kidney showing mild degenerative
A) (210×) when compared to (B) the group that received 120 pmol
merular (asterisk) and tubular epithelial cells with deposition of
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Additional files
Additional file 1: Effects of different doses of MVIIC on total
protein levels. After spinal cord injury, controls were injected with sterile
water (PLA) and other groups received different doses of MVIIC (15, 30,
60 and 120 pmol). Values represent the means ± SD of six animals at
each time.
Additional file 2: Effects of different doses of MVIIC on median
corpuscular volume. After spinal cord injury, controls were injected with
sterile water (PLA) and other groups received different doses of MVIIC
(15, 30, 60 and 120 pmol). Values represent the means ± SD of six animals
at each time.
Additional file 3: Effects of different doses of MVIIC on median
corpuscular hemoglobin. After spinal cord injury, controls were injected
with sterile water (PLA) and other groups received different doses of
MVIIC (15, 30, 60 and 120 pmol). Values represent the means ± SD of six
animals at each time.
Additional file 4: Effects of different doses of MVIIC on mean
corpuscular hemoglobin concentration. After spinal cord injury,
controls were injected with sterile water (PLA) and other groups received
different doses of MVIIC (15, 30, 60 and 120 pmol). Values represent the
means ± SD of six animals at each time.
Additional file 5: Effects of different doses of MVIIC on monocyte
levels. After spinal cord injury, controls were injected with sterile water
(PLA) and other groups received different doses of MVIIC (15, 30, 60 and
120 pmol). Values represent the means ± SD of six animals at each time.
Additional file 6: Effects of different doses of MVIIC on neutrophil
levels. After spinal cord injury, controls were injected with sterile water
(PLA) and other groups received different doses of MVIIC (15, 30, 60 and
120 pmol). Values represent the means ± SD of six animals at each time.
Additional file 7: Effects of different doses of MVIIC on basophil
levels. After spinal cord injury, controls were injected with sterile water
(PLA) and other groups received different doses of MVIIC (15, 30, 60 and
120 pmol). Values represent the means ± SD of six animals at each time.
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